Genmab A/S (Copenhagen:GEN) announced today that the net sales for Arzerra(R) (ofatumumab) during the third quarter of 2010 were approximately DKK 78 million (approximately USD 14 million). Arzerra third quarter net sales in the U.S. and the rest of the world were approximately DKK 69.3 million (approximately USD 12.7 million) and approximately DKK 8.7 million (approximately USD 1.6 million) respectively. Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 15.6 million (approximately USD 2.9 million).
Arzerra was granted accelerated approval by the FDA in October 2009, for the treatment of patients in the U.S. with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. Arzerra was launched by GSK in mid-November 2009. In April 2010, a conditional marketing authorization for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab was granted by the EU Commission.
The conversion to USD has been made using the Danish Central Bank closing spot rate on September 30, 2010 of USD 1.00 = DKK 5.4601.